Hikma Pharmaceuticals USA Inc. is recalling 13,760 vials of Ganciclovir for Injection, USP (500mg per vial). The recall was initiated because one vial within a 10-count carton was mislabeled as Cladribine Injection 10mg/mL. No incidents or injuries have been reported to date. This medication is typically administered in clinical settings like hospitals or infusion centers.
A labeling mix-up could cause a patient to receive Cladribine (a chemotherapy drug) instead of Ganciclovir (an antiviral medication), or vice versa. Administering the incorrect potent medication could lead to serious adverse health consequences or ineffective treatment of the intended condition.
Mfd. by: THYMOORGAN PHARMAZIE GmbH, Germany; Distributed by Hikma Berkeley Heights, NJ 07922
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.